Aronex Pharmaceuticals Inc. is in the unenviable position of losing its invitation to present to an FDA advisory panel after the agency identified deficiencies in the NDA for Atragen injectable all-trans retinoic acid as a treatment for acute promyelocytic leukemia (APL). And although it is theoretically possible that the FDA's review will be completed within the original user fee timetable, the company cannot begin to address the deficiencies because, as of Friday, it